PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck U.S., the U.S. subsidiaries of H. Lundbeck A/S, (Lundbeck) presented new post hoc pooled analyses of two pivotal Phase 3 trials evaluating the safety and efficacy of REXULTI® (brexpiprazole) in patients with agitation associated with dementia due to Alzheimer’s disease.1 The posters were presented on March 16 at the American Association for Geriatric Psychiatry (AAGP) 2024 Annual Meeting in Atlanta..

新泽西州普林斯顿和伊利诺伊州迪尔菲尔德（BUSINESS WIRE）--大冢制药开发与商业化公司（Otsuka）和伦贝克美国公司（Lundbeck U.S.），H.Lundbeck A/S的美国子公司（Lundbeck）对两个关键的3期试验进行了新的事后汇总分析，评估了REXULTI®（brexpiprazole）的安全性和有效性这些海报于3月16日在亚特兰大举行的美国老年精神病学协会（AAGP）2024年年会上发布。。

REXULTI is the first treatment approved by the U.S. Food and Drug Administration (FDA) for agitation associated with dementia due to Alzheimer’s disease.2 Agitation associated with dementia due to Alzheimer’s disease is a common neuropsychiatric condition reported in approximately half of all patients with dementia due to Alzheimer’s disease and one of the most complex and stressful aspects of caring for people living with dementia due to Alzheimer’s disease.3 Agitation symptoms include behaviors such as pacing, gesturing, profanity, shouting, shoving, and hitting.4.

REXULTI是美国食品和药物管理局（FDA）批准的第一种治疗方法与阿尔茨海默病痴呆相关的躁动。阿尔茨海默病痴呆相关的躁动是所有阿尔茨海默病痴呆患者中约一半的常见神经精神疾病，也是照顾阿尔茨海默病痴呆患者最复杂和压力最大的方面之一。3躁动症状包括起搏、手势、亵渎、喊叫、推搡和殴打等行为。

Otsuka and Lundbeck presented three practice-relevant posters containing post hoc analyses on the efficacy of REXULTI in patients with agitation associated with dementia due to Alzheimer’s disease, and caregiver impact at the meeting. One poster utilized the Neuropsychiatric Inventory (NPI) to explore the relationship of REXULTI on neuropsychiatric symptoms relating to agitation and occupational disruptiveness/caregiver distress related to patients’ behavior.

大冢（Otsuka）和伦德贝克（Lundbeck）在会议上展示了三张与实践相关的海报，其中包含了REXULTI对阿尔茨海默氏病（Alzheimer's disease）引起的痴呆症患者躁动的疗效以及护理人员影响的事后分析。一张海报利用神经精神病学量表（NPI）来探索REXULTI与患者行为相关的激动和职业干扰/照顾者痛苦相关的神经精神病学症状之间的关系。

The NPI, which is administered through a structured caregiver interview, is comprised of 12 domains of neuropsychiatric symptoms including agitation/aggression, irritability/lability, and disinhibition. Each domain is scored from best to worst based on frequency, severity, and occupational disruptiveness/caregiver distress.

NPI通过结构化护理人员访谈进行管理，由12个神经精神症状领域组成，包括激动/攻击，烦躁/不稳定和去抑制。根据频率，严重程度和职业干扰/照顾者痛苦，对每个领域从最好到最差进行评分。

The analysis demonstrated that REXULTI was associated with reductions in overall neuropsychiatric symptoms and in agitation symptoms (as captured by the NPI) compared with placebo over 12 weeks. In addition, REXULTI was associated with a greater reduction in occupational disruptiveness/caregiver distress total score compared to placebo, with separation observed as early as Week 4.1.

分析表明，与安慰剂相比，在12周内，REXULTI与整体神经精神症状和躁动症状（由NPI捕获）的减少有关。此外，与安慰剂相比，REXULTI与职业干扰/护理人员痛苦总分的降低更大相关，早在第4.1周就观察到分离。

Another poster explored the efficacy of REXULTI on symptoms of agitation across different patient characteristic subgroups that are common in clinical practice, including baseline dementia severity, care setting, concomitant/prior medication use, and baseline co-occurring NPI symptoms (excluding agitation).

另一张海报探讨了REXULTI对临床实践中常见的不同患者特征亚组的躁动症状的疗效，包括基线痴呆严重程度，护理环境，伴随/既往药物使用以及基线并发NPI症状（不包括躁动）。

A responder analysis based on a meaningful within-patient change threshold of ≥20-point reduction from baseline to Week 12 in the CMAI Total score was also conducted. The post-hoc analysis demonstrated that REXULTI was associated with greater improvement in symptoms of agitation than placebo across all subgroups as measured by the change from baseline in Cohen-Mansfield Agitation Inventory (CMAI) total score at Week 12.5.

还进行了基于CMAI总分从基线到第12周有意义的患者内变化阈值≥20分的响应者分析。事后分析表明，在第12.5周，Cohen-Mansfield躁动量表（CMAI）总分与基线相比的变化表明，在所有亚组中，REXULTI与安慰剂相比，躁动症状的改善程度更大。

The final poster looked at the efficacy and safety of REXULTI in patients grouped by baseline psychosis status (with psychosis and without psychosis), with approximately a quarter of patients presenting with psychosis symptoms at baseline. The analysis showed fixed-dose REXULTI 2 or 3 mg/day was associated with greater improvements in agitation symptoms compared with placebo in both subgroups, as measured by the change in CMAI total score at Week 12.

最后的海报研究了REXULTI在基线精神病状态（有精神病和无精神病）分组的患者中的疗效和安全性，大约四分之一的患者在基线时出现精神病症状。分析显示，固定剂量的REXULTI 2或3毫克/天与安慰剂相比，两个亚组的躁动症状均有较大改善，这是通过第12周CMAI总分的变化来衡量的。

In addition, the safety and tolerability of REXULTI 0.5-3mg/day was similar between the subgroups.6.

此外，REXULTI 0.5-3mg/天的安全性和耐受性在亚组之间相似。

“It’s well known that the effects of dementia due to Alzheimer’s disease extend beyond the patient to caregivers whose lives are often disrupted in order to meet the significant demands of care,” said George T. Grossberg, MD, Department of Psychiatry and Behavioral Neuroscience at Saint Louis University School of Medicine.

圣路易斯大学医学院精神病学和行为神经科学系医学博士乔治·格罗斯伯格（GeorgeT.Grossberg）说：“众所周知，阿尔茨海默氏病引起的痴呆症的影响不仅限于患者，还包括照顾者，他们的生活常被打乱，以满足重要的护理需求。”。

“These new analyses are important because they are the first to explore the potential impact of addressing agitation symptoms with brexpiprazole on caregiver-reported distress.”.

“这些新的分析很重要，因为它们是第一个探索用brexpiprazole解决激动症状对护理人员报告的痛苦的潜在影响的分析。”。

“These data reinforce the urgency to treat agitation separately from dementia due to Alzheimer’s disease and gives prescribers further confidence to choose an FDA-approved therapy to help address these symptoms,” said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka.

大冢（Otsuka）执行副总裁兼首席医疗官、医学博士约翰·克劳斯（JohnKraus）说：“这些数据强化了将激动与阿尔茨海默病痴呆分开治疗的紧迫性，并使开处方者更有信心选择FDA批准的治疗方法来帮助解决这些症状。”。

“We greatly appreciate the efforts of the caregivers and their families that participated in these important clinical trials.”.

“我们非常感谢参与这些重要临床试验的护理人员及其家人的努力。”。

“Family caregivers typically spend more than 20 hours a week caring for a loved one with Alzheimer’s disease,”7 said Johan Luthman, executive vice president, Lundbeck Research & Development. “The breadth of data presented at AAGP represents our continued commitment to understanding the full potential of REXULTI on agitation associated with dementia due to Alzheimer’s disease.”.

伦贝克研究与发展执行副总裁约翰·卢特曼（JohanLuthman）说：“家庭护理人员通常每周花20多个小时照顾患有阿尔茨海默病的亲人。”。“AAGP提供的广泛数据代表了我们继续致力于了解REXULTI对阿尔茨海默病痴呆症相关激动的全部潜力。”。

About Agitation Associated with Dementia Due to Alzheimer’s Disease

关于阿尔茨海默病引起的痴呆相关的激动

Agitation associated with dementia due to Alzheimer’s disease is a common neuropsychiatric symptom that is reported in approximately half of all patients with dementia due to Alzheimer’s disease.3 The condition has a large impact on the quality of life for the patients, family members, and caregivers.3,8.

与阿尔茨海默病痴呆相关的躁动是一种常见的神经精神症状，大约一半的阿尔茨海默病痴呆患者报告了这种症状[3]。这种情况对患者，家属和护理人员的生活质量有很大影响[3,8]。

Agitation associated with dementia due to Alzheimer’s disease covers a large group of behaviors occurring in patients with dementia due to Alzheimer’s disease, such as pacing, gesturing, profanity, shouting, shoving, and hitting.8 Symptoms of agitation are also a consistent predictor of nursing home admission in patients with dementia, including those with Alzheimer’s disease.9-11.

与阿尔茨海默病痴呆相关的激动包括阿尔茨海默病痴呆患者发生的大量行为，如起搏，手势，亵渎，喊叫，推搡和撞击。激动症状也是痴呆患者（包括阿尔茨海默病患者）疗养院入院的一致预测因子。

About Brexpiprazole

布瑞哌唑

Brexpiprazole was approved in the U.S. in 2015 as an adjunctive therapy to antidepressants in adults with major depressive disorder (MDD) and as a treatment for schizophrenia in adults. Brexpiprazole was also approved by Health Canada for schizophrenia and adjunctive treatment of MDD in 2017 and 2019, respectively.

2015年，Brexpiprazole在美国被批准作为成人重度抑郁症（MDD）抗抑郁药的辅助治疗，以及成人精神分裂症的治疗。Brexpiprazole也分别于2017年和2019年被加拿大卫生部批准用于精神分裂症和MDD的辅助治疗。

It was approved by the Ministry of Health, Labour and Welfare in Japan and by the European Medicines Agency (EMA) in 2018 for the treatment of schizophrenia..

2018年，它被日本厚生劳动省和欧洲药品管理局（EMA）批准用于治疗精神分裂症。。

Brexpiprazole was discovered by Otsuka and is being co-developed by Otsuka and Lundbeck. The mechanism of action of brexpiprazole is unknown, however the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors..

布雷匹唑是大冢发现的，大冢和伦贝克正在共同开发。brexpiprazole的作用机制尚不清楚，但是brexpiprazole的功效可能是通过5-羟色胺5-HT1A和多巴胺D2受体的部分激动剂活性以及5-羟色胺5-HT2A受体的拮抗剂活性的组合来介导的。。

INDICATIONS and IMPORTANT SAFETY INFORMATION for REXULTI® (brexpiprazole)

REXULTI®（brexpiprazole）的适应症和重要安全信息

INDICATIONS:

适应症：

REXULTI is a prescription medicine used:

REXULTI是一种处方药，用于：

along with antidepressant medicines to treat major depressive disorder (MDD) in adults

与抗抑郁药物一起治疗成人重度抑郁症（MDD）

to treat schizophrenia in adults and children ages 13 years and older

治疗成人和13岁及以上儿童的精神分裂症

to treat agitation that may happen with dementia due to Alzheimer’s disease

治疗阿尔茨海默病痴呆症可能发生的躁动

REXULTI should not be used as an “as needed” treatment for agitation that may happen with dementia due to Alzheimer’s disease.

REXULTI不应被用作“根据需要”治疗阿尔茨海默病痴呆症可能发生的躁动。

It is not known if REXULTI is safe and effective in children with MDD.

目前尚不清楚REXULTI对MDD儿童是否安全有效。

It is not known if REXULTI is safe and effective in children under 13 years of age with schizophrenia.

目前尚不清楚REXULTI对13岁以下精神分裂症儿童是否安全有效。

IMPORTANT SAFETY INFORMATION:

重要安全信息：

Increased risk of death in elderly people with dementia-related psychosis. Medicines like REXULTI can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). REXULTI is not approved for the treatment of people with dementia-related psychosis without agitation that may happen with dementia due to Alzheimer’s disease..

痴呆相关精神病老年人死亡风险增加。像REXULTI这样的药物会增加老年人的死亡风险，这些老年人由于混乱和记忆力丧失（痴呆症）而失去了与现实（精神病）的联系。REXULTI未被批准用于治疗痴呆相关精神病患者，而不会因阿尔茨海默氏病引起的痴呆症而引起躁动。。

Increased risk of suicidal thoughts and actions. REXULTI and antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. Depression and other mental illnesses are the most important causes of suicidal thoughts and actions.

自杀念头和行为的风险增加。REXULTI和抗抑郁药物可能会增加一些24岁及以下人群的自杀念头和行为，尤其是在治疗的头几个月内或剂量改变时。抑郁症和其他精神疾病是自杀念头和行为的最重要原因。

Patients on antidepressants and their families or caregivers should watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. Report any change in these symptoms immediately to the doctor..

服用抗抑郁药的患者及其家人或护理人员应注意新的或恶化的抑郁症状，尤其是情绪，行为，思想或感觉的突然变化。立即向医生报告这些症状的任何变化。。

Do not take REXULTI if you are allergic to brexpiprazole or any of the ingredients in REXULTI.

如果您对brexpiprazole或REXULTI中的任何成分过敏，请不要服用REXULTI。

REXULTI may cause serious side effects, including:

REXULTI可能会引起严重的副作用，包括：

Cerebrovascular problems, including stroke, in elderly people with dementia-related psychosis that can lead to death.

老年痴呆相关精神病患者的脑血管问题，包括中风，可能导致死亡。

Neuroleptic malignant syndrome (NMS) is a serious condition that can lead to death. Call your healthcare provider or go to the nearest hospital emergency room right away if you have some or all of the following signs and symptoms of NMS: high fever; changes in your pulse, blood pressure, heart rate, and breathing; stiff muscles; confusion; increased sweating.

抗精神病药物恶性综合征（NMS）是一种严重的疾病，可导致死亡。如果您有以下NMS的部分或全部体征和症状，请立即致电您的医疗保健提供者或前往最近的医院急诊室：高烧；脉搏、血压、心率和呼吸的变化；肌肉僵硬；混乱；出汗增加。

Uncontrolled body movements (tardive dyskinesia). REXULTI may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking REXULTI. Tardive dyskinesia may also start after you stop taking REXULTI.

不受控制的身体运动（迟发性运动障碍）。REXULTI可能会导致面部、舌头或其他身体部位无法控制的运动。迟发性运动障碍可能不会消失，即使你停止服用REXULTI。停止服用REXULTI后，迟发性运动障碍也可能开始。

Problems with your metabolism such as:

新陈代谢问题，例如：

high blood sugar (hyperglycemia) and diabetes. Increases in blood sugar can happen in some people who take REXULTI. Extremely high blood sugar can lead to coma or death. Your healthcare provider should check your blood sugar before you start, or soon after you start REXULTI and then regularly during long term treatment with REXULTI..

高血糖（高血糖）和糖尿病。服用雷克多的一些人可能会出现血糖升高。极高的血糖会导致昏迷或死亡。您的医疗保健提供者应该在您开始之前或开始使用REXULTI后不久检查您的血糖，然后在使用REXULTI进行长期治疗期间定期检查。。

Call your healthcare provider if you have any of these symptoms of high blood sugar during treatment with REXULTI:

如果您在使用REXULTI治疗期间出现任何这些高血糖症状，请致电您的医疗保健提供者：

feel very thirsty

感到非常口渴

feel very hungry

感觉很饿

feel sick to your stomach

胃部不舒服

need to urinate more than usual

需要比平时排尿更多

feel weak or tired

感到虚弱或疲倦

feel confused, or your breath smells fruity

感到困惑，或者你的呼吸有水果味

increased fat levels (cholesterol and triglycerides) in your blood. Your healthcare provider should check the fat levels in your blood before you start, or soon after you start REXULTI, and then periodically during treatment with REXULTI.

血液中脂肪水平（胆固醇和甘油三酯）升高。您的医疗保健提供者应在您开始使用REXULTI之前或之后不久检查您血液中的脂肪水平，然后在使用REXULTI治疗期间定期检查。

weight gain. You and your healthcare provider should check your weight before you start and often during treatment with REXULTI.

体重增加。您和您的医疗保健提供者应该在开始之前检查您的体重，并且经常在使用REXULTI治疗期间检查体重。

Unusual and uncontrollable (compulsive) urges. Some people taking REXULTI have had strong unusual urges, to gamble and gambling that cannot be controlled (compulsive gambling). Other compulsive urges include sexual urges, shopping, and eating or binge eating. If you or your family members notice that you are having new or unusual strong urges or behaviors, talk to your healthcare provider..

不寻常且无法控制（强迫）的冲动。一些服用REXULTI的人有强烈的异常冲动，赌博和无法控制的赌博（强迫性赌博）。其他强迫性冲动包括性欲、购物、进食或暴饮暴食。如果您或您的家人注意到您有新的或不寻常的强烈冲动或行为，请与您的医疗保健提供者联系。。

Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment with REXULTI.

白细胞计数低。您的医疗保健提供者可能会在使用REXULTI治疗的前几个月进行血液检查。

Decreased blood pressure (orthostatic hypotension) and fainting. You may feel dizzy, lightheaded or pass out (faint) when you rise too quickly from a sitting or lying position.

血压下降（体位性低血压）和晕厥。当你从坐着或躺着的姿势起得太快时，你可能会感到头晕、头晕或昏厥。

Falls. REXULTI may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries.

跌倒。REXULTI可能会使您昏昏欲睡或头晕，在改变姿势时可能会导致血压下降（体位性低血压），并会减慢您的思维和运动技能，从而导致跌倒，从而导致骨折或其他伤害。

Seizures (convulsions).

癫痫发作（抽搐）。

Problems controlling your body temperature so that you feel too warm. Do not become too hot or dehydrated during treatment with REXULTI. Do not exercise too much. In hot weather, stay inside in a cool place if possible. Stay out of the sun. Do not wear too much clothing or heavy clothing. Drink plenty of water..

控制体温的问题使你感到太热。在使用REXULTI治疗期间，不要太热或脱水。不要运动太多。天气炎热时，尽可能呆在阴凉的地方。远离阳光。不要穿太多衣服或厚重的衣服。多喝水。。

Difficulty swallowing that can cause food or liquid to get into your lungs.

吞咽困难，可能导致食物或液体进入肺部。

Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities. Do not drive a car, operate machinery, or do other dangerous activities until you know how REXULTI affects you. REXULTI may make you feel drowsy.

困倦、困倦、感觉疲倦、思维困难和正常活动。在了解雷克斯多对您的影响之前，请勿驾驶汽车、操作机器或进行其他危险活动。REXULTI可能会让你感到昏昏欲睡。

Before taking REXULTI, tell your healthcare provider about all of your medical conditions, including if you:

服用REXULTI之前，请告知您的医疗保健提供者您的所有医疗状况，包括您是否：

have or have had heart problems or a stroke

患有或曾经患有心脏病或中风

have or have had low or high blood pressure

患有或曾经患有低血压或高血压

have or have had diabetes or high blood sugar or a family history of diabetes or high blood sugar. Your healthcare provider should check your blood sugar before you start REXULTI and during treatment with REXULTI.

患有或曾经患有糖尿病或高血糖或有糖尿病或高血糖家族史。您的医疗保健提供者应该在您开始使用REXULTI之前和使用REXULTI治疗期间检查您的血糖。

have or have had high levels of total cholesterol, LDL cholesterol, or triglycerides, or low levels of HDL cholesterol

总胆固醇、低密度脂蛋白胆固醇或甘油三酯水平高，或高密度脂蛋白胆固醇水平低

have or have had seizures (convulsions)

癫痫发作（抽搐）

have or have had kidney or liver problems

有或曾经有肾脏或肝脏问题

have or have had a low white blood cell count

白细胞计数低

are pregnant or plan to become pregnant. REXULTI may harm your unborn baby. Taking REXULTI during your third trimester of pregnancy may cause your baby to have abnormal muscle movements or withdrawal symptoms after birth. Talk to your healthcare provider about the risk to your unborn baby if you take REXULTI during pregnancy..

怀孕或计划怀孕。REXULTI可能会伤害您的未出生婴儿。在怀孕的第三个三个月服用REXULTI可能会导致婴儿出生后出现异常的肌肉运动或戒断症状。与您的医疗保健提供者讨论怀孕期间服用REXULTI对未出生婴儿的风险。。

Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with REXULTI.

如果您在使用REXULTI治疗期间怀孕或认为自己怀孕了，请告知您的医疗保健提供者。

There is a pregnancy exposure registry for women who are exposed to REXULTI during pregnancy. If you become pregnant during treatment with REXULTI, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/..

有一个怀孕暴露登记处，用于怀孕期间接触雷克斯多的女性。如果您在使用REXULTI治疗期间怀孕，请与您的医疗保健提供者联系，向国家妊娠登记处注册非典型抗精神病药物。您可以拨打1-866-961-2388或访问http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/..

are breastfeeding or plan to breastfeed. It is not known if REXULTI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with REXULTI.

正在母乳喂养或计划母乳喂养。目前尚不清楚REXULTI是否会进入你的母乳。与您的医疗保健提供者讨论在使用REXULTI治疗期间喂养宝宝的最佳方式。

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. REXULTI and other medicines may affect each other causing possible serious side effects. REXULTI may affect the way other medicines work, and other medicines may affect how REXULTI works.

告诉你的医疗保健提供者你服用的所有药物，包括处方药和非处方药、维生素和草药补充剂。REXULTI和其他药物可能会相互影响，导致可能的严重副作用。REXULTI可能会影响其他药物的工作方式，其他药物可能会影响REXULTI的工作方式。

Your healthcare provider can tell you if it is safe to take REXULTI with your other medicines. Do not start or stop any medicines during treatment with REXULTI without first talking to your healthcare provider..

您的医疗保健提供者可以告诉您与其他药物一起服用REXULTI是否安全。在使用REXULTI治疗期间，未事先与您的医疗保健提供者交谈，请勿开始或停止任何药物。。

The most common side effects of REXULTI include weight gain, sleepiness, dizziness, common cold symptoms, and restlessness or feeling like you need to move (akathisia).

REXULTI最常见的副作用包括体重增加，嗜睡，头晕，常见的感冒症状，烦躁不安或感觉需要运动（静坐不能）。

These are not all the possible side effects of REXULTI. For more information, ask your healthcare provider or pharmacist.

这些并不是REXULTI所有可能的副作用。有关更多信息，请咨询您的医疗保健提供者或药剂师。

You are encouraged to report side effects of REXULTI (brexpiprazole). Please contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

鼓励您报告雷克多（brexpiprazole）的副作用。请致电1-800-438-9927联系Otsuka America Pharmaceutical，Inc.或致电1-800-FDA-1088联系FDA（www.FDA.gov/medwatch）。

Please read FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE for REXULTI.

请阅读完整的处方信息，包括盒装警告和REXULTI用药指南。

About Otsuka

关于大冢

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: Otsuka–people creating new products for better health worldwide. Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health..

大冢制药有限公司是一家全球性的医疗保健公司，其企业理念是：大冢-人们创造新产品以改善全球健康。大冢研究、开发、制造和销售创新产品，重点是满足未满足医疗需求的医药产品和维持日常健康的营养保健产品。。

In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does..

在制药领域，大冢在精神、肾脏和心血管健康等具有挑战性的领域处于领先地位，并在肿瘤学和包括结核病（一个重要的全球公共卫生问题）在内的一些未得到充分解决的疾病方面拥有额外的研究项目。这些承诺说明大冢在本质上是一家“大风险”公司，在其所做的每件事中都运用了年轻的创造力。。

Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies’ 2,000 employees in the U.S. develop and commercialize medicines in the areas of mental health and nephrology, using cutting-edge technology to address unmet healthcare needs..

大冢于1973年在美国成立了分支机构，如今其美国分支机构包括大冢制药开发与商业化公司（OPDC）和大冢美国制药公司（OAPI）。这两家公司在美国的2000名员工利用尖端技术开发心理健康和肾脏病领域的药物并将其商业化，以满足未满足的医疗需求。。

OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 47,000 people worldwide and had consolidated sales of approximately USD 14.2 billion in 2023.

OPDC和OAPI是大冢制药有限公司的间接子公司，大冢制药有限公司是大冢控股有限公司的子公司，总部位于日本东京。大冢集团在全球拥有47000名员工，2023年的合并销售额约为142亿美元。

All Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at https://www.otsuka.co.jp/en/.

所有大冢的故事都是从走人迹罕至的路开始的。有关大冢在美国的更多信息，请访问www.Otsuka-us.com，并通过LinkedIn和Twitter@OtsukaUS与我们联系。大冢制药有限公司的全球网站可访问https://www.otsuka.co.jp/en/.

About Lundbeck

关于伦贝克

Lundbeck US refers to the wholly owned US subsidiaries of H. Lundbeck A/S (HLUNa / HLUNb, HLUNA DC / HLUNB DC), a global pharmaceutical company specialized in brain diseases, including Lundbeck LLC and Lundbeck Pharmaceuticals LLC. For more than 70 years, we have been at the forefront of neuroscience research.

Lundbeck US是指H.Lundbeck A/S（HLUNa/HLUNb，HLUNa DC/HLUNb DC）的全资美国子公司，这是一家专门从事脑部疾病的全球制药公司，包括Lundbeck LLC和Lundbeck Pharmaceuticals LLC。70多年来，我们一直处于神经科学研究的前沿。

We are tirelessly dedicated to restoring brain health, so every person can be their best..

我们孜孜不倦地致力于恢复大脑健康，因此每个人都可以做到最好。。

We have approximately 5,400 employees in more than 50 countries, and our products are available in more than 100 countries. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options.

我们在50多个国家拥有约5400名员工，我们的产品遍布100多个国家。我们的研究项目解决了神经科学中一些最复杂的挑战，我们的管道专注于为几乎没有治疗选择的脑部疾病提出变革性治疗方法。

We have research facilities in Denmark and the United States, and our production facilities are located in Denmark, France and Italy..

我们在丹麦和美国拥有研究设施，我们的生产设施位于丹麦、法国和意大利。。

In the United States, H. Lundbeck A/S subsidiaries, including Lundbeck LLC and Lundbeck Pharmaceuticals LLC, employ more than 1,000 people focused solely on accelerating therapies for brain disorders. With a special commitment to the lives of patients, families and caregivers, Lundbeck US actively engages in a broad range of initiatives each year that support patient communities..

在美国，包括Lundbeck LLC和Lundbeck Pharmaceuticals LLC在内的H.Lundbeck A/S子公司雇用了1000多名员工，他们专注于加速脑部疾病的治疗。凭借对患者、家属和护理人员生活的特殊承诺，伦贝克美国每年都积极参与支持患者社区的广泛举措。。

For additional information, we encourage you to visit us at lundbeck.com/us and connect with us on LinkedIn and Twitter at @LundbeckUS.

欲了解更多信息，我们鼓励您访问lundbeck.com/us，并通过LinkedIn和Twitter@LundbeckUS与我们联系。

References

参考文献

Brubaker M, Wang D, Chumki S, et al. Efficacy of Brexpiprazole Across Agitation Behaviors in Alzheimer’s Disease, Including Impact on Caregivers, Analyzed Using the Neuropsychiatric Inventory: a Post Hoc Pooled Analysis of Randomized, Fixed-dose, Placebo-controlled Trials. American Association for Geriatric Psychiatry (AAGP), Atlanta, Ge., March-15-18, 2024..

Brubaker M，Wang D，Chumki S等。使用神经精神病学量表分析了Brexpiprazole对阿尔茨海默病激越行为的疗效，包括对护理人员的影响：随机，固定剂量，安慰剂对照试验的事后汇总分析。美国老年精神病学协会（AAGP），亚特兰大，Ge，2024年3月15日至18日。。

FDA News Release. FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease. Published: May 11, 2023. Last accessed: Feb 20, 2024. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease.

FDA新闻稿。FDA批准了第一种治疗阿尔茨海默病痴呆相关躁动症状的药物。出版日期：2023年5月11日。上次访问时间：2024年2月20日。网址：https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease.

Halpern R, Seare J, Tong J, Hartry A, Olaoye A, Aigbogun MS. Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia. Int J Geriatr Psychiatry. 2019;34(3):420-431.

Halpern R，Seare J，Tong J，Hartry A，Olaoye A，Aigbogun MS.使用电子健康记录来估计阿尔茨海默病/痴呆症中躁动的患病率。Int J老年精神病学。2019年；34（3）：420-431。

Cummings J, Mintzer J, Brodaty H, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015;27(1):7-17.

Cummings J，Mintzer J，Brodaty H等。认知障碍中的激动：国际老年心理协会临时共识临床和研究定义。国际心理老人。2015年；27（1）：7-17。

Brubaker M, Wang D, Chumki S, et al. Efficacy of Brexpiprazole in Patients With Agitation Associated With Dementia Due to Alzheimer’s Disease Analyzed by Patient Characteristics: a Post Hoc Pooled Analysis of Randomized, Fixed-dose, Placebo-controlled Trials. American Association for Geriatric Psychiatry (AAGP), Atlanta, Ge., March-15-18, 2024..

Brubaker M，Wang D，Chumki S等。根据患者特征分析布雷哌唑对阿尔茨海默病痴呆伴躁动患者的疗效：随机、固定剂量、安慰剂对照试验的事后汇总分析。美国老年精神病学协会（AAGP），亚特兰大，Ge，2024年3月15日至18日。。

Behl S, Chang D, Chen D, et. al. Efficacy of Brexpiprazole in Patients with Agitation Associated With Alzheimer’s Dementia Analyzed by Presence or Absence of Psychosis: a Pooled Analysis. American Association for Geriatric Psychiatry (AAGP), Atlanta, Ge., March-15-18, 2024.

Behl S，Chang D，Chen D，et al。通过是否存在精神病来分析Brexpiprazole对与阿尔茨海默病痴呆相关的躁动患者的疗效：汇总分析。美国老年精神病学协会（AAGP），亚特兰大，Ge，2024年3月15日至18日。

Alzheimer’s Association. 2015 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia 2015;11(3)332. Last accessed: 07 Mar, 2024. Available at: https://www.alz.org/media/documents/2015factsandfigures.pdf

阿尔茨海默氏症协会。2015年阿尔茨海默病事实和数字。阿尔茨海默病与痴呆2015；11（3）332。上次访问时间：2024年3月7日。网址：https://www.alz.org/media/documents/2015factsandfigures.pdf

Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, et al. Impact of agitation in long-term care residents with dementia in the United States. Int J Geriatr Psychiatry. 2021;36(12):1959-1969.

Fillit H，Aigbogun MS，Gagnon-Sanschagrin P等人。激动对美国痴呆症长期护理居民的影响。Int J老年精神病学。2021年；36（12）：1959-1969年。

Gaugler JE, Yu F, Krichbaum K, Wyman JF. Predictors of nursing home admission for persons with dementia [published correction appears in Med Care. 2009 May;47(5):606]. Med Care. 2009;47(2):191-198.

Gaugler JE，Yu F，Krichbaum K，Wyman JF。痴呆症患者入住疗养院的预测因素[已发表的更正发表在Med Care上。2009年5月；47（5）：606]。医疗保健。2009年；47（2）：191-198。

Kales HC, Chen P, Blow FC, Welsh DE, Mellow AM. Rates of clinical depression diagnosis, functional impairment, and nursing home placement in coexisting dementia and depression. Am J Geriatr Psychiatry. 2005;13(6):441-449.

Kales HC，Chen P，Blow FC，Welsh DE，Mellow AM。痴呆和抑郁症并存的临床抑郁症诊断，功能障碍和疗养院安置率。我是J老年精神病学。2005年；13（6）：441-449。

Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA. 2002;287(16):2090-2097.

Yaffe K，Fox P，Newcomer R等人。痴呆患者的患者和护理人员特征以及疗养院安置。杰玛。2002年；287（16）：2090-2097。